chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Within a few days of the first vaccine, patient experienced pain, numbness, and tingling in his toes L>R. After this, the pain diminished, but he noticed swelling and redness in his toes. Over the next few weeks, he noticed black patches on the toes. Now, he is noticing darkening/bruising on the toe nails
I started feeling badly on 5/24 with a fever, chills, and fatigue and I had already been informed that I was exposed to my son who tested positive for Covid on 5/22. As my symptoms progressed, I took an at home Covid test which was negative. I also called my doctor who prescribed an albuterol inhaler and Beclomethasone dipropionate HSA inhaler. I retested at home on 5/27 again with a home kit and the results were positive. I reached out again to my physician who prescribed Paxlovid. My symptoms have improved but are still present. I am still using all of my prescribed medication and some over the counter medications for treatment. I did noticed marked improvement in my symptoms after beginning the antiviral.
(A) PAIN, SWELLING, REDNESS, BRUISING ON ARM (B) PERIODICALLY, I FELT "HYPER" REPID HEART BEAT LIKE HAVING AN OVERDOSE OF CAFFEINE (CONSIDERED A SEVERE SIDE EFFECT ON VACCINE INFORMATION SHEET.)
observed significant redness & swelling involving rt upper extremity including forearm p/anthrax #2;also noticed rt sided neck swelling w/mild difficulty swallowing;no resp sx;Tx w/motrin, ice w/minimal relief;
Severe vomiting, fever, tremors, seizures, stopped eating, ended up with a g-tube to feed her.
Had painless worms on the bottom of the foot for almost 20 years, and have; chills; fatigue; This spontaneous case was reported by a consumer and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (Had painless worms on the bottom of the foot for almost 20 years, and have), CHILLS (chills) and FATIGUE (fatigue) in a 33-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039A21A) for COVID-19 vaccination.     Concurrent medical conditions included Ringworm of foot (Painless worms on the bottom of the foot for almost 20 years), Joint pain and Allergy NOS. Concomitant products included GLUCOSAMINE for Joint pain, COLECALCIFEROL (VITAMIN D [COLECALCIFEROL]) for an unknown indication.    On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021, the patient experienced CHILLS (chills) and FATIGUE (fatigue). On an unknown date, the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (Had painless worms on the bottom of the foot for almost 20 years, and have). On 25-Mar-2021, CHILLS (chills) and FATIGUE (fatigue) had resolved. At the time of the report, THERAPEUTIC RESPONSE UNEXPECTED (Had painless worms on the bottom of the foot for almost 20 years, and have) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Concomitant products included Histamine used for allergies. No treatment medications were reported.   This case was linked to MOD-2021-414638 (Patient Link).
arm very painful; swollen and tender left axillary and left supraclavicular nodes; swollen and tender left axillary and left supraclavicular nodes; chills; red x 5 days; This is a spontaneous report from a contactable healthcare professional (patient). This 48-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number EL3249; dose 2) via an unspecified route of administration on 20Jan2021 at 1:30 PM (at the age of 48-years-old) as a single dose in the left arm for COVID-19 immunization. Medical history included hypertension and mild asthma. The patient was not pregnant at the time of vaccination. It was unknown if the patient had COVID-19 prior to vaccination. The patient took concomitant medications which were unspecified. The patient did not received any other vaccines within four weeks prior to the vaccination. The patient previously took penicillin on unknown dates for an unknown indication and experienced allergy. The patient received dose 1 of BNT162B2 (lot number: EL0104) on 30Dec2020 at 11:30 AM in the left arm as a single dose for COVID-19 immunization. On an unspecified date after the second vaccination, the patient had arm very painful, red for 5 days, and swollen and tender left axillary and left supraclavicular nodes. On 21Jan2021, 24 hours after the vaccine, the patient experienced chills lasting three to four hours. The patient did not have adverse effects at all after the first vaccine. The events resulted in a doctor or other healthcare professional office/clinic visit. The patient did not received treatment for the events. The outcomes of arm very painful and red, swollen and tender left axillary and left supraclavicular nodes, and chills were recovering. It was also reported that since the vaccination the patient had not been tested for COVID-19.  No follow-up attempts are needed. No further information is expected.
My finger has been hurting since my last vaccine; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP), Program ID: The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "My finger has been hurting since my last vaccine".  Additional information: My finger has been hurting since my last vaccine. I would like to talk with someone about my pain.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
This spontaneous report as received from a licensed practical nurse refers to an unspecified number of patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant medications were not reported. On an unknown dates in 2016 (reported as "since 05-OCT-2016"), the patients were vaccinated with an unspecified number of doses of improperly stored ROTATEQ orally, lot# M004885 with expiration date: 23-OCT-2017 and lot# M007298 with expiration date: 19-NOV-2017 (dose was not reported). Administered doses of ROTATEQ underwent temperature excursions at 35 Fahrenheit degrees, for 45 hours. There were no previous temperature excursions. Data logger was involved. No adverse effects were reported. Product quality complaint (PQC) was not involved. This is one of two reports received from the same reporter. Additional information has been requested.
pt recv vax 21OCT96 & on 24OCT96 pt devel raised lesions on both thighs (anterior);
heart beat went up a little bit; temperature of 105°F; fatigued; 5in long 3in across rash on the injection arm; This spontaneous case was reported by a consumer and describes the occurrence of HEART RATE INCREASED (heart beat went up a little bit), PYREXIA (temperature of 105°F), FATIGUE (fatigued) and INJECTION SITE RASH (5in long 3in across rash on the injection arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HEART RATE INCREASED (heart beat went up a little bit), PYREXIA (temperature of 105°F), FATIGUE (fatigued) and INJECTION SITE RASH (5in long 3in across rash on the injection arm). At the time of the report, HEART RATE INCREASED (heart beat went up a little bit), PYREXIA (temperature of 105°F), FATIGUE (fatigued) and INJECTION SITE RASH (5in long 3in across rash on the injection arm) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 105 degree f (Inconclusive) 105 Degree F.         No concomitant medications were reported. No information regarding corrective treatment was reported by the patient.   This case was linked to US-MODERNATX, INC.-MOD-2021-035080 (E2B Linked Report).   Reporter did not allow further contact; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-035080:dose 1
Developed sensation of "lump" in throat.  No rash, itching, chest tightness or shortness of breath.  BP 100/67, P 90 and  O2 Sat 98%.  Symptom resolved after 20 minutes.
At 1625 patient started feeling  lightheaded and had a metallic taste in mouth and had some tingling in her right knee.  Had patient lay in recliner and gave apple juice, she felt much better after 5 minutes and insisted on leaving.
Patient presented to the pharmacy to report adverse reaction, but had a slurred speech/ difficulty to speak, tingling  fingers, numbness in feet, muscle weakness, nausea
2 doses with a 6 weeks interval; This case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 71-year-old male patient who received Herpes zoster (Shingrix) (batch number y4la9, expiry date 25th May 2023) for prophylaxis.   Concomitant products included RECOMBINANT VARICELLA ZOSTER VIRUS SURFACE GLYCOPROTEIN E (SHINGRIX).   On 15th February 2022, the patient received the 2nd dose of Shingrix. On 15th February 2022, unknown after receiving Shingrix, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown.  Additional details were provided as follows: The age at vaccination was unknown. On 4th January 2022, the patient received 1st dose of Shingrix. The patient received the 2nd dose of Shingrix earlier than the recommended schedule with a 6 weeks interval, which led to shortening of vaccination schedule. No further events were reported. The Vaccine administration facility was the same as Primary reporter. The reporter consented to follow up.
mild flu like symptoms; This spontaneous case was reported by an other health care professional and describes the occurrence of INFLUENZA LIKE ILLNESS (mild flu like symptoms) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Rheumatoid arthritis and Osteoarthritis (walks with cane.). Concomitant products included HYDROCODONE, GABAPENTIN, CLONAZEPAM (KLONOPIN), IBUPROFEN, VITAMIN D3 and ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) for an unknown indication.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (mild flu like symptoms). At the time of the report, INFLUENZA LIKE ILLNESS (mild flu like symptoms) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment medication was reported.
severe symptoms after her second Gardasil vaccine; This spontaneous report was received from a physician via IQVIA, concerning  a female patient of an unknown age. The patient's medical history, concurrent conditions and concomitant therapies were not provided.     On an unspecified date, the patient was vaccinated with the second dose of quadrivalent human papillomavirus (types 6,11,16,18) recomb. Vaccine (GARDASIL) (dose, frequency, route, lot#, expiration date were not provided) as prophylaxis.             On an unknown date, after the second vaccine, the patient experienced severe symptoms, therefore her mother contacted me last fall for an appointment. Action taken with quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL) was not reported. At the time of the report, the outcome of the event was not reported.    The causal relationship between the event and quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(GARDASIL) was considered as related.
Vaccine went into 2-8 degree Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date; Vaccine went into 2-8 degree Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date; This spontaneous case was reported by a health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 degree Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 degree Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Feb-2022 at 4:33 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 19-Feb-2022 at 4:33 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 degree Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 degree Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 degree Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 degree Celsius thaw state on or about 24-Dec-2021 and administered on vaccine administration date) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant product reported by reporter. Vaccine went into 2 to 8 degree Celsius in thaw state on or about 24 Dec 2021. No treatment medication reported by reporter.
death Narrative:  Patient received Moderna covid vaccine #1 on 3/25/21. No notes entered after this time and date of death is recorded as 3/30/21. No scanned records. No autopsy results available. 5 days from date of vaccine to date of death.
Covid-19 treatment; Covid-19 treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 35-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 22Dec2021 as dose 3 (booster), single (Lot number: FE3594) at the age of 34 years for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset May2023, outcome "unknown" and all described as "Covid-19 treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19 with Paxlovid (start date: 09May2023, stop date: 13May2023).  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300198809 same patient, different drug/event;
NSTEMI - hospital admission. This visit was within 6 weeks of receiving the COVID vaccine.
24 hours post vax, the pt developed a mild temperature elevation to 100.7 with generalized redness, swelling, and warmth over right deltoid. She also developed redness, swelling, warmth, and tenderness over left upper arm.
Overnight after the injection - Uncontrollably shaking, high fever, weakness, loss of appetite, hot flashes Next day - weakness, loss of appetite Three days later - hot flashes, weakness
Higher fever developed 48 hours after administration, ceased. Extreme arm pain developed approximately 12 hours after administration radiates down to fingers. Could barely lift arm. Got better but still painful and throbbing.
SLEEP IS WORSE; RASH ALL OVER HIS BODY, FACE, NECK, SHOULDERS, LEGS, THIGHS, STOMACH, BACK AND SHOULDERS; This spontaneous report received from a patient concerned a 79 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included: heart condition, high blood pressure, and arthritis. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1808978 and expiry: 11-SEP-2021) dose was not reported, administered on 05-MAY-2021 for prophylactic vaccination. No concomitant medications were reported.  On JUN-2021, the patient experienced rash all over his body, face, neck, shoulders, legs, thighs, stomach, back and shoulders. On JUL-2021, treatment medications included: menthol/zinc oxide. On AUG-2021, Laboratory data included: Blood test (NR: not provided) not reported, and Urine analysis (NR: not provided) not reported. On an unspecified date, the patient experienced sleep is worse. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from rash all over his body, face, neck, shoulders, legs, thighs, stomach, back and shoulders, and sleep is worse. This report was non-serious.
Patient passed out and fell to the floor.  She was very dizzy and nauseous.  She may have also hit her head on the floor when she fell.  She stayed laying down until she felt better and then sat up.  She said her neck also her, and she used an ice pack.  A nurse was with me, helping with paper work and she helped to monitor her. Patient called a friend to take her home once she was feeling better so she wasn't left alone.
passed out several times and vomits; passed out several times and vomits; This is a spontaneous report from a non-contactable consumer. This consumer reported similar event for two patients. This the second of two reports.  A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) dose number was unknown, single dose for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. The reporter stated that their neighbor's boyfriend (patient) had passed out several times and vomits. The reporter asked if there was a clinical trial to study these side effects. Outcome of the events was unknown.    No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202100956275 Same reporter, same drug and event, different patient
Sore arm for 3 days. Flu like symptoms for 2 days. Chills, every joint ached like I had been beaten. It wasn't as bad as the first dose, but still horrible:(
Systemic: stiff neck, metallic taste in mouth-Mild, Systemic: Nausea-Mild
later to be diagnosed with shingles; Individual reports forgetting to get second shingles vaccine; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of shingles in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix and the patient did not receive 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced shingles (Verbatim: later to be diagnosed with shingles) and incomplete course of vaccination (Verbatim: Individual reports forgetting to get second shingles vaccine).  The outcome of the shingles was not reported and the outcome of the incomplete course of vaccination was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix and Shingrix.     It was unknown if the company considered the shingles to be related to Shingrix and Shingrix.   Additional Information: GSK Receipt Date:11-OCT-2023 The patient reported about forgetting to get second shingles vaccine. The patient had 1st dose and later to be diagnosed with shingles. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.
vision loss; eye pain; This is a spontaneous report from a non-contactable consumer (patient). An adult female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 18Mar2021 (Batch/Lot number was not reported) as single dose for Covid-19 immunization. It was unknown if the patient was pregnant at the time of vaccination. Medical history included Factor V Leiden, PCOS (Polycystic ovarian syndrome), and POTS (Postural orthostatic tachycardia syndrome), all from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. It was unknown if the patient was not diagnosed with COVID-19 prior to vaccination. It was unknown if the patient received any other vaccines within 4 weeks prior to the COVID vaccine. The patient experienced eye pain and then vision loss on 20Mar2021, 2 days after vaccination. It was unknown if the patient received treatment for the adverse event. The adverse events resulted in Doctor or other healthcare professional office/clinic visit, Disability or permanent damage. It was unknown if the patient has not been tested for COVID-19 since the vaccination. The outcome of events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
headache, cognitive change / brain fog, fatigue, word finding difficulties subacute onset headache now resolved cognitive change / brain fog continues to occur intermittently now over several years
it was painful where he was given the COVID vaccine but he had no symptoms; This is a spontaneous report from a contactable consumer (patient).   An adult male patient of an unspecified age received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route of administration on 17Apr2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. The patient had received the first dose of vaccine on unknown date at the top of the arm and had minimal to no pain (only some swelling upon administration). The patient medical history and the patient's concomitant medications were not reported.  The patient experienced "it was painful where he was given the covid vaccine but he had no symptoms" (vaccination site pain) on an unspecified date with outcome of unknown.    The clinical course was as follows, "cold transfer from unknown department and caller says that he has symptoms but the whole thing started when he had his first COVID vaccine and he felt nothing. With his second shot he is not sure about it. The guy who gave the caller his second COVID vaccine did it on the side of his arm and the caller had doubts that it may of not gone in all the way into his muscle and let's just say it didn't- so put that question on the side. Then it was painful where he was given the COVID vaccine but he had no symptoms. Then a week or so later, and now, he has a little bit of pain there or a sensation."  No follow-up attempts are needed; Information related to batch/Lot number could not be requested.
Within one week of the vaccine I felt like I had pressure on my chest and chest pain and I was having a problem breathing. I had a cough and I had shortness of breath. I was really tired. I had that feeling of tiredness for one week. The shortness of breath and tiredness lasted two weeks. I used my inhaler when I needed it and after three weeks it feels better and I no longer have any symptoms.